You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

45 Results
Guidelines and Advice
Status: Current
ID: PET 7
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 6
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Status: Archived
ID: 15-7
Mar 2009
Guidelines and Advice
Status: Archived
ID: 3-16
Jul 2009
Guidelines and Advice
Status: Archived
ID: 15-6
Mar 2009
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Guidelines and Advice
Status: Current
ID: GL-C50-05
Jan 2009
Drug
Other Name(s): Perjeta®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
methotrexate,
vinBLAStine,
DOXOrubicin,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
DOCEtaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022

Pages